Immunology: Current Research
Open Access

Immune tolerance; Autoimmune diseases; Regulatory T cells; Central tolerance; Peripheral tolerance; Autoimmunity; Molecular mechanisms.

Introduction

The immune system’s ability to distinguish between self and non-self is fundamental to preventing autoimmune diseases. Autoimmunity occurs when this tolerance is lost, and immune cells attack the body's own tissues, leading to diseases such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. Immune tolerance mechanisms, both central and peripheral, are responsible for ensuring this self/non-self-distinction [1,2]. Central tolerance occurs primarily in the thymus and bone marrow, where self-reactive immune cells are deleted, while peripheral tolerance mechanisms regulate immune responses in the periphery. Central tolerance is a process that eliminates self-reactive T and B cells during their development. This is crucial for preventing the emergence of autoreactive lymphocytes that could lead to autoimmunity [3,4]. The thymus plays a central role in selecting T cells that can recognize self-antigens, and the bone marrow ensures that only non-self-reactive B cells mature. However, central tolerance is not foolproof, and some autoreactive cells can escape into the peripheral circulation. Peripheral tolerance mechanisms act as a secondary line of defense. Regulatory T cells (Tregs) are a key component, acting to suppress autoreactive immune cells. These cells are critical in maintaining immune homeostasis and preventing the development of autoimmune diseases [5]. In addition to Tregs, immune checkpoints such as PD-1, CTLA-4, and others help regulate immune responses by inhibiting the activation of self-reactive lymphocytes. Furthermore, emerging evidence suggests that the microbiome, environmental factors, and genetic predispositions also influence immune tolerance and contribute to the development of autoimmune diseases [6]. Understanding the molecular mechanisms of immune tolerance and their role in autoimmune disease pathogenesis can aid in the development of targeted therapies to restore tolerance and treat autoimmune conditions.

Results

Recent studies have elucidated the various molecular pathways involved in immune tolerance, revealing both redundancies and unique functions for different tolerance mechanisms. Central tolerance in the thymus is primarily governed by the interaction of T cell receptors (TCRs) with self-antigens presented by medullary thymic epithelial cells (mTECs). This interaction is crucial for negative selection, where T cells that strongly bind to self-antigens are eliminated. The transcription factor AIRE (Autoimmune Regulator) plays a significant role in this process, facilitating the expression of tissue-specific antigens in the thymus, thus promoting the deletion of autoreactive T cells. Peripheral tolerance involves a combination of mechanisms to control immune responses after T and B cells have matured. Regulatory T cells (Tregs) are key to maintaining peripheral tolerance. These cells express the transcription factor Foxp3, which is essential for their suppressive function. Tregs can inhibit the activation of self-reactive T cells and B cells through a variety of mechanisms, including cytokine secretion and direct cell-to-cell contact. In addition to Tregs, immune checkpoints such as PD-1 and CTLA-4 play critical roles in maintaining tolerance by suppressing the activation of autoreactive immune cells. Recent studies have demonstrated that these checkpoints are dysregulated in autoimmune diseases, further emphasizing their importance in immune tolerance. The role of the microbiome in modulating immune tolerance is also becoming increasingly clear. Dysbiosis, or an imbalance in the gut microbiota, has been associated with the development of autoimmune diseases, suggesting that microbial signals can influence immune tolerance mechanisms. Furthermore, environmental factors such as infections and exposure to toxins can alter immune responses, potentially triggering the onset of autoimmune diseases in genetically predisposed individuals.

Discussion

The molecular mechanisms of immune tolerance play a pivotal role in preventing autoimmunity. Central tolerance, while effective, is not entirely foolproof. The thymic deletion of self-reactive T cells ensures that only those with weak or no affinity for self-antigens are allowed to mature. However, some self-reactive T cells can escape this process and enter the periphery, where peripheral tolerance mechanisms take over [7]. Regulatory T cells (Tregs) are crucial in maintaining peripheral tolerance, and their dysfunction or insufficient numbers have been implicated in the pathogenesis of autoimmune diseases. The role of immune checkpoints such as PD-1, CTLA-4, and others in preventing autoimmunity is becoming increasingly recognized. These checkpoints inhibit T cell activation when bound to their ligands, providing a safeguard against excessive immune responses. In autoimmune diseases, the failure of these checkpoints can result in the activation of autoreactive T cells, leading to tissue damage. Targeting these checkpoints has shown promise in restoring tolerance in autoimmune diseases, as seen in the use of checkpoint inhibitors in cancer immunotherapy. Additionally, the microbiome has emerged as a critical player in regulating immune tolerance [8]. Dysbiosis, or an imbalance in the microbial communities of the gut, has been linked to several autoimmune conditions, including inflammatory bowel disease (IBD) and rheumatoid arthritis. The microbiome influences the development of both Tregs and the systemic immune response, highlighting the intricate relationship between host genetics, environmental exposures, and immune system function. Lastly, environmental factors such as infections, toxins, and dietary components can influence immune tolerance mechanisms. In genetically predisposed individuals, these factors may trigger the onset of autoimmune diseases. Understanding how these factors contribute to immune tolerance breakdown could lead to preventive strategies for autoimmune diseases.

Conclusion

The maintenance of immune tolerance is a delicate and complex process that is essential for preventing autoimmune diseases. Central tolerance mechanisms, including the elimination of self-reactive T and B cells in the thymus and bone marrow, play a critical role in safeguarding the immune system against autoimmunity. However, peripheral tolerance mechanisms, including the function of regulatory T cells and immune checkpoints, are equally important in preventing autoreactive immune responses in the periphery. Disruption of these processes can result in the development of autoimmune diseases. Recent advancements in understanding the molecular mechanisms involved in immune tolerance have provided insights into potential therapeutic strategies for treating autoimmune diseases. Restoring immune tolerance through targeted therapies, such as checkpoint inhibitors or Treg-based therapies, holds promise for reversing autoimmune conditions. Additionally, the growing recognition of the microbiome’s role in modulating immune tolerance underscores the need for a more holistic approach to autoimmune disease prevention and treatment. The interplay between genetic predispositions, environmental factors, and immune tolerance mechanisms highlights the complexity of autoimmune disease pathogenesis. Future research should continue to explore the molecular pathways involved in immune tolerance to identify new therapeutic targets and improve the management of autoimmune diseases. By understanding the delicate balance between immune activation and tolerance, we can better address the growing burden of autoimmune diseases globally.

Acknowledgment

None

Conflict of Interest

None

References

1. Chen DF, Hu L, Yi P, Liu WW, Fang DC, et al. (2007) Hpylori are associated with chronic cholecystitis. World J Gastroenterol 13: 1119-1122.

Indexed at, Google Scholar, Crossref

2. Bedhiafi T, Inchakalody VP, Fernandes Q, Mestiri S, Billa N, et al. (2022) The potential role of vitamin C in empowering cancer immunotherapy. Biomed Pharmacotherap 146: 112553.

Indexed at, Google Scholar, Crossref

3. Kumar V, Kono DH, Urban JL, Hood L (1989) The T-cell receptor repertoire and autoimmune diseases. Annu rev immunol 7: 657-682.

Indexed at, Crossref

4. Islam MR, Islam F, Nafady MH, Akter M, Mitra S, et al. (2022) Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint. Molecules 27: 2165.

Indexed at, Google Scholar, Crossref

5. Pandey PR, Young KH, Kumar D, Jain N (2022) RNA-mediated immunotherapy regulating tumor immune microenvironment: Next wave of cancer therapeutics. Mol Cancer 21: 1-18.

Indexed at, Google Scholar, Crossref

6. Alemohammad H, Basira N, Zahra A, Amir B, Ghorbaninezhad F, et al. (2022) The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacotherap 146: 112516.

Indexed at, Google Scholar, Crossref

7. Zhong Z, Vong CT, Chen F, Tan H, Zhang C, et al. (2022) Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. Med Res Rev 42: 1246-1279.

Indexed at, Google Scholar, Crossref

8. Danesh J, Wong Y, Ward M, Muir J (1999) Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart 81: 245-247.

Indexed at, Google Scholar, Crossref